TNFSF13B
|
0.090 |
Biomarker
|
disease |
BEFREE |
The administration of belimumab, a monoclonal antibody specific for BAFF and approved for lupus therapy, could potentiate the efficacy of rituximab and enable longer periods of disease remission.
|
31848169 |
2019 |
TNFSF13B
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Since excessive B cell-activating factor belonging to the TNF family (BAFF) expression correlates with human and murine lupus, and BAFF signals B cell survival through BAFF-R, it is believed that excessive BAFF-R signaling can subvert B cell tolerance and facilitate lupus development.
|
18200501 |
2008 |
TNFSF13B
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The aim of the current study is to explore whether serum BAFF levels along with variants of the BAFF gene increase lupus related atherosclerotic risk.
|
29859654 |
2018 |
TNFSF13B
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of BAFF and APRIL have shown inconsistent relationships with lupus disease activity.
|
27804111 |
2017 |
TNFSF13B
|
0.090 |
Biomarker
|
disease |
BEFREE |
BAFF is an important pathogenic factor in lupus mouse models and BAFF inhibition successfully delays disease onset in these mice, although the responsiveness to BAFF inhibition varies among different strains.
|
21333645 |
2011 |
TNFSF13B
|
0.090 |
Biomarker
|
disease |
BEFREE |
Treatment with murine ICOSL/BAFF bispecific or combination therapy was more efficacious than single ICOSL or BAFF inhibitor in mouse NZB/NZW lupus model.
|
30789152 |
2019 |
TNFSF13B
|
0.090 |
Biomarker
|
disease |
BEFREE |
G-744 is efficacious, and superior to blocking BAFF and Syk, in ameliorating severe lupus nephritis in both spontaneous and IFNα-accelerated lupus in NZB/W_F1 mice in therapeutic regimens.
|
28405610 |
2017 |
TNFSF13B
|
0.090 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to determine whether BAFF, a key pathogenic factor in systemic lupus erythematosus, also a dichotomous regulator for B-cell immune responses, has an effect on IL-35-producing regulatory B cells and their underlying mechanisms in lupus.
|
28844943 |
2017 |
TNFSF13B
|
0.090 |
Biomarker
|
disease |
BEFREE |
Thus, we have identified a novel role for BCMA to control excess BAFF production in murine lupus through restraining the accumulation of BAFF-producing neutrophils.
|
25010693 |
2014 |